DAX24.915 +0,3%Est505.985 -0,4%MSCI World4.343 -0,1%Top 10 Crypto8,7200 +5,5%Nas22.547 -0,2%Bitcoin58.762 +1,3%Euro1,1861 -0,1%Öl67,75 +0,3%Gold5.043 +2,5%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
Rheinmetall 703000 Amazon 906866 NVIDIA 918422 SAP 716460 Siemens Energy ENER6Y Deutsche Telekom 555750 Siemens 723610 Microsoft 870747 Deutsche Bank 514000 Lufthansa 823212 Mercedes-Benz Group (ex Daimler) 710000 Commerzbank CBK100 BASF BASF11 Allianz 840400 DroneShield A2DMAA
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
Nach Inflationsdaten: US-Börsen letztlich uneins -- DAX geht etwas fester ins Wochenende -- Amazon im Bärenmarkt -- Delivery Hero, pbb, Siemens, RWE, Rivian, Adyen, Apple, Arista im Fokus
Top News
Delisting: Was passiert, wenn eine Aktie von der Börse genommen wird Delisting: Was passiert, wenn eine Aktie von der Börse genommen wird
Angebot wächst weiter: 59 Kryptowährungen bei finanzen.net zero verfügbar Angebot wächst weiter: 59 Kryptowährungen bei finanzen.net zero verfügbar
Suche...
Login
ODER

Neu auf finanzen.net?

Kostenfrei registrieren und Vorteile nutzen

Übersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil

Astellas Pharma Aktie

Kaufen
Verkaufen
Aktien-Sparplan anlegen
13,80 EUR +0,28 EUR +2,03 %
BMN
2.510,50 JPY +40,50 JPY +1,64 %
TOKIO
Astellas Pharma jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)
Smartphone

Marktkap.24,40 Mrd. EUR

KGV51,03Div. Rendite5,12%
WKN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

WKN856273

ISIN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

ISINJP3942400007

Symbol wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

SymbolALPMF

Astellas Pharma Aktien News

DatumMeistgelesen
PR NewswireVYLOY™ (zolbetuximab) Plus Chemotherapy Associated with Enhanced Survival Outcomes when Common Adverse Events are Effectively Managed, According to New Ad Hoc Analyses
PR NewswireAstellas to Present at 44th Annual J.P. Morgan Healthcare Conference
PR NewswirePADCEV™ Plus Keytruda® Significantly Improves Survival for Patients with Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility
Wer­bungAstellas Pharma-Aktie für 0 Euro (zzgl. Spreads) handeln bei finanzen.net zero
PR NewswireAstellas to Present New Clinical Data Across Its Gastrointestinal Cancers Portfolio at 2026 ASCO GI Cancers Symposium
PR NewswireAstellas To Present New Data on XOSPATA™ (gilteritinib) Across the FLT3m+ AML Disease Continuum at ASH 2025 Annual Meeting
PR NewswireAstellas and the Internet's Favorite Grandma, Barbara 'Babs' Costello, Partner to Encourage Others to Get Ahead of Geographic Atrophy (GA)
PR NewswireAstellas Presents Preliminary Real-World VEOZAH™ (fezolinetant) Data From OPTION-VMS Phase IV Observational Study
PR NewswirePADCEV™ (enfortumab vedotin-ejfv) Plus KEYTRUDA® (pembrolizumab) sBLA Granted FDA Priority Review for Treatment of Certain Patients with Muscle-Invasive Bladder Cancer
PR NewswireIZERVAY™ (avacincaptad pegol intravitreal solution) Showed Increased Benefit in Reducing Geographic Atrophy Progression Over Time and Consistent Long-Term Safety
PR NewswirePADCEV™ Plus KEYTRUDA™, Given Before and After Surgery, Cuts the Risk of Recurrence, Progression or Death by 60% and the Risk of Death by 50% for Certain Patients with Bladder Cancer
PR NewswireAstellas to Present New Data on IZERVAY™ (avacincaptad pegol intravitreal solution) in Geographic Atrophy at AAO 2025 Annual Meeting
PR NewswireAstellas To Present Pioneering Advances Across Its Portfolio and Pipeline at ESMO 2025
PR NewswireAstellas Announces Top Management Personnel Change
PR NewswireAstellas Announces a Partnership with the "Korea Institute of Startup and Entrepreneurship Development", an Umbrella Organization of the "Ministry of SMEs and Startups", a Korean Government Agency...
PR NewswireMitsubishi Research Institute and Astellas Announce Collaboration to Support Pharma Startups in Japan
ZacksAre Medical Stocks Lagging Astellas Pharma (ALPMY) This Year?
PR NewswireAstellas Enters Exclusive License Agreement with Evopoint Biosciences for XNW27011, a Novel Clinical-stage Antibody-Drug Conjugate Targeting CLDN18.2
PR NewswireAstellas Announces Second Annual Patient Advocacy Organization (PAO) Action Week™ To Empower Patients and Caregivers
ZacksIs Astellas Pharma (ALPMY) Stock Outpacing Its Medical Peers This Year?
PR NewswireAstellas and Pfizer's XTANDI™ (enzalutamide) Shows Long-Term Overall Survival in Metastatic Hormone-Sensitive Prostate Cancer
PR NewswireAstellas and MBC BioLabs Announce the 2025 Astellas Future Innovator Prize Awarded to DeepSeq.AI & Serna Bio
PR NewswireAstellas Presents New Data that Explores Potential of its Cancer Therapies at 2025 ASCO Annual Meeting
ZacksHere's Why Astellas Pharma (ALPMY) Is a Great 'Buy the Bottom' Stock Now
PR NewswireNotice of Nominees for Directors
PR NewswireAstellas to Present New Data in Geographic Atrophy at Upcoming Ophthalmology Annual Congresses
ZacksAstellas Pharma (ALPMY) Upgraded to Strong Buy: What Does It Mean for the Stock?
ZacksIs Astellas Pharma (ALPMY) Outperforming Other Medical Stocks This Year?
PR NewswireAstellas and YASKAWA Agree to Establish a Joint Venture Focused on Cell Therapy Manufacturing
PR NewswireAstellas and MBC BioLabs Announce the Sixth Annual Astellas Future Innovator Prize
PR NewswireU.S. FDA Approves Expanded Label for Astellas' IZERVAY™ (avacincaptad pegol intravitreal solution) for Geographic Atrophy
PR NewswireAstellas Submits New Drug Application for Conditional Approval of Avacincaptad Pegol for Geographic Atrophy in Japan
PR NewswireAstellas Makes Announcement about Management Structure
PR NewswireU.S. FDA Confirms Class 1 Resubmission of the Supplemental New Drug Application for IZERVAY™ (avacincaptad pegol intravitreal solution) for Geographic Atrophy
PR NewswireChina's National Medical Products Administration (NMPA) Approves PADCEV™ in combination with KEYTRUDA® (pembrolizumab) for the Treatment of Advanced Bladder Cancer
PR NewswireChina's National Medical Products Administration (NMPA) Approves VYLOY™ (zolbetuximab) for First-Line Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
PR NewswireAstellas and Sangamo Therapeutics Announce Capsid License Agreement to Deliver Genomic Medicines for Neurological Diseases
PR NewswireAstellas Announces Desert Oasis Healthcare as First Health System to Implement DIGITIVA™ for Heart Failure Management
PR NewswireAstellas' VYLOY™ (zolbetuximab-clzb) Approved by U.S. FDA for Treatment of Advanced Gastric and GEJ Cancer
PR NewswireFDA Grants iota Biosciences IDE Approval for First-In-Human Early Feasibility Study with Implantable Bladder Device
PR NewswireAstellas and AviadoBio Announce Exclusive Option and License Agreement for Gene Therapy AVB-101 Targeting Frontotemporal Dementia and Other Indications

Astellas Pharma News

Astellas Pharma News: auf dieser Seite finden Sie alle Astellas Pharma News und Nachrichten zur Astellas Pharma Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Astellas Pharma News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Astellas Pharma News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.